Evaluation of Genetic Polymorphisms of N-acetyltransferase 2 and Relation with Chronic Myeloid Leukemia

Document Type : Research Articles


1 Faculty of Medical Laboratory Sciences, Department oF Hematology, Al Neelain University, Sudan.

2 Faculty of Applied Medical Sciences, Clinical Laboratory Sciences, Shaqra University, Saudi Arabia.

3 Faculty of Medical Laboratory Sciences, Al Neelain Stem Cell Center, Al Neelain University, Sudan.

4 School of Pharmacy and Biomedical Sciences, University of Portsmouth, UK.

5 Faculty of Applied Medical Sciences, Clinical Laboratory Sciences, Jouf University, Saudi Arabia.

6 Faculty of Medical Laboratory Sciences, Department of Hematology, University of El Imam El Mahdi, Sudan.


Objectives: The N-Acetyltransferase 2 (NAT2) gene encodes a key enzyme involved in xenobiotic metabolism, which contributes to the detoxification of numerous cancer therapy-induced products. However, the NAT2 genotype/phenotype is not fully understood and few studies have reported its relationship with CML. The aim of this study was to determine whether its polymorphisms (C481T, G590A, 803A>G and 857G>A) have a role in chronic myeloid leukemia susceptibility (CML) in Sudanese population. Methods: We performed a case- control study. DNA from 200 CML patients and 100 controls was analyzed for the NAT2 polymorphisms using PCR-RFLP assay. Results: The study showed NAT2 polymorphisms 803AG are associated with CML protection by a factor of 2.3, (OR = 0.044, 95% CI: 0.020-0.095, p = 0. 000). The study indicated that the heterozygous (GA) and mutant (AA) variants of the G857A genotype also offer protection, (OR = 0.002, 95% CI: 0.002-0.019, p = 0. 000) and (OR = 0.018, 95% CI: 0.002-0.133, p = 0. 000), respectively. Conclusion: There was no significant difference in CML diagnosis among Sudanese cases with the 481C→T and 590G→A polymorphisms. But patients with the compound NAT2 genotypes 481CT/803 AG, 590AG/ 803AG, 590AG/ 803GG, 590AA/ 803AG and 590GG/ 803AG were found to have a reduced risk. The current study demonstrates that polymorphisms of NAT2 A803G and G857A might also act as protective factors against developing the disease.


Main Subjects

Volume 21, Issue 12
December 2020
Pages 3711-3717
  • Receive Date: 01 May 2020
  • Revise Date: 12 July 2020
  • Accept Date: 19 December 2020
  • First Publish Date: 19 December 2020